Risk Factors for Disease Progression Following Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus–Associated Oropharynx Squamous Cell Carcinoma (HPV-OSCC)

Authors :: Ashish V. Chintakuntlawar
Jan L. Kasperbauer
J.C. Rwigema
J.R. Janus
Samir H. Patel
Daniel J. Ma
K.R. Bailey
Yolanda I. Garces
Scott C. Lester
Christine M. Lohse
Eric J. Moore
D.L. Price
J.J. Garcia
K. Van Abel
Michelle A. Neben-Wittich
Kerry D. Olsen
K. Price
Lisa A. McGee
Robert L. Foote
Michael L. Hinni
Source :: International Journal of Radiation Oncology*Biology*Physics. 106:1124
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Oropharynx squamous cell carcinoma
Radiation
business.industry
Disease progression
Internal medicine
medicine
Radiology, Nuclear Medicine and imaging
Human papillomavirus
business
Adjuvant chemoradiotherapy
De-escalation

Tools